跳至主要内容
临床试验/CTIS2024-513251-32-00
CTIS2024-513251-32-00进行中(未招募)1 期

Role of contrast enhanced mammography with Iomeprol 400 mgI/ml (Iomeron, Bracco), in the identification of breast cancer: I3-MaC Study - I3-MaC Study

Azienda Ospedaliero-Universitaria Policlinico Umberto I0 个研究点目标入组 173 人开始时间: 2024年3月28日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
173

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • Female patients = 35 years of age • Patients who underwent mammography during the 5 weeks prior to enrollment in the study • Patients with a breast lesion requiring further assessment with biopsy ? BIRADS 4 or 5 breast lesion seen at mammography ? Suspicion of malignancy of a lesion seen at ultrasound and not evaluable with mammography • Patients who provide their written informed consent and are willing to comply with protocol requirements

排除标准

  • Renal insufficiency (eGFR below 30 mL/min using the MDRD equation [MDRD=Modification of Diet in Renal Disease]) • Allergy to iodinated contrast agents • BRCA 1 or 2 mutation • Pregnant or lactating females; subjects in post-partum • Severe hypertension (systolic blood pressure >100 under treatment or uncontrolled hypertension with systolic pressure >160 and/or diastolic pressure >90)

研究者

发起方
Azienda Ospedaliero-Universitaria Policlinico Umberto I

相似试验